1 BTC
=
- USD
Acumen Pharmaceuticals, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Acumen Pharmaceuticals, Inc. Common Stock
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Market Statistics
Trading Metrics
How to Buy ABOS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ABOS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesAcumen Pharmaceuticals reported Q1 2026 financial results with cash reserves of $128.4 million. The company expects topline results from its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026, and plans to file an IND for its lead EBD program candidate in mid-2027. R&D expenses decreased to $16.5 million from $25.3 million year-over-year due to reduced manufacturing and CRO costs following ALTITUDE-AD enrollment completion.
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 14, 2026. The company is advancing its lead candidate sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers, in its Phase 2 ALTITUDE-AD trial for early symptomatic Alzheimer's disease, with topline results expected in late 2026.
Acumen Pharmaceuticals announced it will report first quarter 2026 financial results on May 12, 2026, with a conference call and webcast at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, with topline results from the Phase 2 ALTITUDE-AD trial expected in late 2026.
Acumen Pharmaceuticals announced it will report Q4 and year-end 2025 financial results on March 26, 2026, with a conference call at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials.
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials following positive Phase 1 results.